48 results about "CagA" patented technology

The invention relates to a gene detection kit, in particular to a helicobacter pylori (HP) type and drug-resistant mutation gene detection kit. The kit comprises PCR (polymerase chain reaction) solutions and nucleic acid membrane strips for HP type and drug-resistant mutation gene detection; the PCR solutions comprise a PCR solution I, a PCR solution II, a PCR solution III and a PCR solution IV; the PCR solutions also contain a pair of internal control primers respectively. The HP type and drug-resistant mutation gene detection kit can be used for distinguishing two types of HP in one test, and can be used for detecting 15 mutation types of 9 hot spot mutational loci related with drug fastness of 5 therapeutics, a VacA gene and a CagA gene are used for typing, and a reference basis is provided for judgment of illnesses. Mutation types of drug-resistant mutation detection are more and more comprehensive, and the condition of genotypic resistance of HP from which a patient suffers is quickly and comprehensively evaluated.

The invention relates to a multiple-gene helicobacter pylori detection system and a kit and application thereof. The helicobacter pylori detection system includes 21 pairs of primers respectively for a strain identification gene (16S rRNA), virulence genes (cagA, vacA-s1, vacA-s2, vacA-m1, vacA-m2, iceA1, iceA2, dupA, oipA and luxS), drug resistance genes (2143 locus of 23S rRNA, 148 locus of rdxA, 1777 locus of pbp1A and polymorphism of the 261 locus of gyrA) and quantitative analysis genes ureC and beta-globin of the helicobacter pylori. The multiple-gene helicobacter pylori detection system and the kit of the system do not need the steps including conventional isolated culture and the like, synchronous detection and analysis on strain identification, quantification, virulence and medicine resistance can be directly conducted on tissue samples in the same reaction system, the shortcomings of low flux, long consumed time, low detection rate and the like of a conventional detection method are overcome, a comprehensive, accurate and low-cost etiological diagnosis is clinically provided for the first time, and important references are provided for individualized diagnosis and accurate treatment of helicobacter pylori infection.

The invention relates to a detection kit for helicobacter pylori virulence protein antibody and a detection method by using the same. The kit comprises a microwell plate, an enzyme-labeled secondary antibody, a negative control serum, a positive control serum, a substrate, a stop buffer and a washing liquor, wherein the microwell plate is coated with purified recombinant helicobacter pylori virulence proteins, the substrate is a solution containing 1% m/m 3, 3', 5, 5'-tetramethyl benzidine and 30% v/v hydrogen peroxide, and the recombinant helicobacter pylori virulence proteins are cytotoxin-associated protein CagA, vacuolating toxin protein VacA, flagellum protein subunit A, flagellum protein subunit B, urease subunit A, and urease subunit B. According to the invention, six purified helicobacter pylori virulence proteins are used as antigens which itself have high conservatism and specificity and are related to the symptom of a patient, so the kit has characteristics of high specificity, identification capacity for helicobacter pylori clinical strain virulence strength, and semi-quantitative detection capacity.

The invention discloses a preparation method of an egg yolk antibody containing helicobacter pylori resisting IgY and an application of the egg yolk antibody. By the aid of a virulent helicobacter pylori immune laying hen with positive CagA genes, the egg yolk antibody is extracted from eggs laid by the laying hen and/or egg yolk powder is prepared. The egg yolk powder with the egg yolk antibody is added into food or prepared into health care food and can be used for preventing related diseases caused by infection of helicobacter pylori in an assisting manner, and the antibody can be prepared into medicines after being purified and is used for preventing the related diseases caused by infection of the helicobacter pylori.

The invention discloses an anti-helicobacter pylori egg yolk antibody, which is prepared by immunizing an egg laying hen by immunizing an egg laying hen by injecting a mixture rich in three proteins,i.e., Ure, VacA and CagA separated from Hp lysate, wherein the mixture is used as an immunogen, and then extracting the purified antibody from egg yolk of the immunized hen by using a water dilution method, a sodium chloride salting-out method and a sulfurophilic affinity chromatography method. The egg yolk antibody prepared by the method is high in purity, has a stronger activity of neutralizinghelicobacter pylori, and can be applied to preparation of medicines for preventing and treating gastrointestinal diseases caused by infection of the helicobacter pylori.

The invention relates to a system for detecting multiple quantitative and virulent genes of H.pylori as well as kits and applications of the system. The system for detecting multiple quantitative and virulent genes of H.pylori comprises multiple pairs of primers, each for strain identification genes (16S rRNA), quantitative analysis genes ureCand Beta-globin, as well as virulent genes (cagA, vacA-s1, vacA-s2, vacA-m1, vacA-m2, iceA1, iceA2, dupA, oipA and luxS). The system for detecting multiple quantitative and virulent genes of H.pylori and the kits of the system can directly perform synchronous detection and analysis on the strain identification, quantification and virulence of a tissue sample in a same reaction system without adopting a conventional culture step or other steps, remedy defects that a conventional detection method is low in throughput, time-consuming and low in detection rate, obviously improve the accuracy of detection results, immediately provide a comprehensive, accurate and low-cost etiological diagnosis for clinic, and provide an important reference for the accurate diagnosis, differential diagnosis and disease prognosis of H.pylori infection.

The invention discloses a helicobacter pylori serotype classification method and a helicobacter pylori biochip construction method. According to the methods, helicobacter pylori is extracted from a patient with helicobacter pylori; the extracted helicobacter pylori has PCR (polymerase chain reaction) of cagA and vacA and is sequenced; after sequencing for helicobacter pylori virulence genes cagA and vacA is finished, a regional virulence epidemic strain is screened out based on gene combination and is named; lipopolysaccharide and flagellum of the helicobacter pylori virulence epidemic strain are extracted and subjected to structural analysis, and serotype naming is performed according to virulence genes, the structure of the flagellum, the Lewis blood type structure of lipopolysaccharide and repeated oligosaccharide structure; and lipopolysaccharide and flagellum of the named strain are extracted to construct the biochip. The helicobacter pylori serotype classification method and the helicobacter pylori biochip construction method can greatly simplify detection means, has the characteristics of high accuracy, high throughput and high repeatability, and can meet requirements of clinical diagnosis, specific treatment and epidemiological investigation for helicobacter pylori.

The present invention provides a method for using lactoferrin for treatment or prevention of helicobacter pylori infection, and in particular, the present invention provides application of the lactoferrin in preparation of a composition for inhibiting helicobacter pylori and a composition for preventing or treating helicobacter-pylori-associated diseases. Tests show that recombinant lactoferrin can effectively inhibit the helicobacter pylori, and has a significant inhibiting effect on helicobacter pylori (Hp) virulence factor cagA, vacA and ure gene expression. In addition, when a lactoferrin preparation is compatibly used for a patient, the efficacy of conventional triple or quadruple therapy can be strengthened, so that the lactoferrin has a broad business prospect.

The invention relates to a detection reagent card for typing test of helicobacter pylori. The detection reagent card comprises a sample pad, a quantum pad, a nitrocellulose membrane, absorbent paper and a lining plate, wherein a quantum dot microsphere labeled antigen complex is coated on the quantum pad; the antigen complex comprises a Urease antigen, a CagA antigen, a VacA antigen and rate IgG;a first detection line, a second detection line, a third detection line and a quality control line are arranged on the nitrocellulose membrane; the VacA antigen is coated on the first detection line;the CagA antigen is coated on the second detection line; the Urease antigen is coated on the third detection line; and the goat anti-rat IgG is coated on the quality control line. The detection reagent card for typing test of helicobacter pylori provided by the invention is capable of rapidly and accurately obtaining the results, the infection type of the helicobacter pylori can be judged according to the detection result, and auxiliary diagnosis is further provided for clinical related diseases.

The invention provides a colloidal gold typing detection test strip for Helicobacter pylori. The test strip includes a support plate, and a sample pad, a gold standard pad, and nitrocellulose are arranged in sequence from the sample loading end on the surface of the support plate. These four parts are the plain film and the absorbent pad. The gold standard pad contains colloidal gold-labeled anti-human IgG Fc segment monoclonal antibody; Four detection lines and quality control lines for foamy toxin (VacA) antigen, HP urease subunit A protein antigen and HP urease subunit B protein antigen, and the above four detection lines and quality control lines do not overlap with each other. The test strip of the present invention belongs to the non-invasive detection technology, can detect 4 kinds of Helicobacter pylori antibodies of urease A, urease B, Cag/A and Vac/A at the same time, adopts the internationally recognized standard Helicobacter pylori strain and quality Control serum to ensure the reliability of detection. The operating method of the test strip is simple, fast and popular, and has application prospects and potential social value.

The invention provides a protein chip for typing detection on helicobacter pylori infection. The protein chip comprises a basement membrane and antigens which are respectively dotted on the basement membrane in the form of dot matrix, wherein the antigens include three types, i.e. CagA (cytotoxin-associated gene) antigens, VacA (Vacuolating cytotoxin A) antigens and Ure (ureaplasma urealyticum) antigens. Due to the fact that the detection antigens used by the protein chip are three single proteins, i.e. Ure, CagA and VacA, specific IgG antibodies for the three antigens in the blood serum of a patient can be detected at the same time, I-type infection or II-type infection can be judged, and clinic treatment is better facilitated; furthermore, the protein chip has the advantages of high detection sensitivity, quick, simple and convenient detection, instant readability, small using amount of antigen and the like.

The invention belongs to the technical field of biology, and discloses a kit for classificatory detection of helicobacter pylori. The kit comprises a blotting membrane transferred with whole helicobacter pylori protein subjected to electrophoretic separation. The kit is used for detecting multiple Hp antibodies such as pathogenic factor cytotoxin (CagA), vacuolating cytotoxin (VacA) and urease subunit A and B antibodies in the serum of a helicobacter pylori infected person by adopting immuno-blotting, determining whether the infected Hp produces strains or not according to different Hp antibodies and further judging the serological types of the Hp strains infecting patients. The kit only requires an examinee to provide the serum, belongs to noninvasive examination, and is high in compliance of the patients, quick in detection (the whole time is only 2 hours), low in demand of samples (only 10 milliliters of examined serum is required), high in specificity, high in sensitivity, wide in application range and convenient to popularize and use in hospitals and hygiene departments.

The invention belongs to the field of biotechnology, and discloses a kit for typing detection of helicobacter pylori. The kit comprises a blotting membrane transferred with helicobacter pylori whole cell lysate protein obtaind by electrophoretic separation. Various Hp antibodies including pathogenic factor cytotoxicity (CagA), vacuole (VacA) and urease subunit A and antibody B contained in the serum of the helicobacter pylori infected patients can be detected by adopting an immunoblotting method, whether infected HP produces strain can be determined according to different HP antibodies so as to further judge the serology type of the infected Hp strain of the patients. According to the kit, patients to be detected only needs to provide serum, tests belong to non-invasive examination, the compliance of the patients is good, the detection is fast as the whole time only lasts for 2 hours, the sample size is small as only 10mu L of to-be-detected serum is needed, the specificity is strong, the sensitivity is high, the application range is wide, and the kit is convenient for popularization and use in hospitals and hygiene departments at all levels.

The invention relates to a medicine selection model and a special plasmid, in particular to a medicine selection model and a special plasmid thereof relevant to the TGF-Beta signal channel. The reported plasmid provided by the invention is a recombinant expression vector obtained after a serial sequence consisting of 12 CAGA-boxes, an adenovirus major later promoter sequence and a reported protein code gene sequence is inserted into a plurality of cloning points of the mammal cell expression vectors. The selection model of medicines relevant to the TGF- Beta signal channel provided by the invention is a human liver cancer cell system which contains the reported plasmid. The selection model of the medicines relevant to the TGF- Beta signal channel of the invention is reliable and stable and is characterized by greatly-promoted selection efficiency, reduced selection cost, shortened selection cycle, reduced tested compound amount and reduced radioactive pollution. Therefore, the medicine selection model of the invention can be applied to the development of relevant medicines to reduce development cost and accelerate the development process; in this way, the invention has broad application prospects.

Provided are an oligonucleotide primer set for amplifying at least one target sequence of the cagA gene of Helicobacter pylori, a method of detecting Helicobacter pylori using the primer set, and a kit for detecting Helicobacter pylori, including the primer set.

The invention relates to a method for preparing a targeted lidamycin production strain by utilizing a gene disruption strain. The method comprises a step of introducing an expression plasmid of a fusion gene, which contains lidamycin apoprotein gene and a fusion gene consisting of different tumor targeted molecular coding sequences, into a lidamycin apoprotein gene disruption strain to obtain the lidamycin production strain with the target corresponding to the target of the tumor targeted molecule, wherein the gene interruption strain is a Streptomyces globisporus C-1027 lidamycin apoprotein gene (cagA) interruption strain, namely S.globisporus AKO; and the tumor targeted molecule includes, but not limited to tumor targeted antibody, tumor targeted peptide, cell factor and the like. The invention also relates to application of the production strain prepared by the method in producing targeted lidamycin.